Genes in the service of therapeutic index: progress for virus-directed enzyme prodrug therapy.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Clinical Oncology

• Publication date

  2004-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1200/JCO.2004.02.921PMID 15051753
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.

  2004cited by this paper
• Antibody-directed enzyme-prodrug therapy.

  2004cited by this paper
• Current developments in cancer vaccines and cellular immunotherapy.

  2003cited by this paper
• Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.

  2003cited by this paper
• Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.

  2003cited by this paper
• Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer.

  2003cited by this paper
• Oncolytic Viruses: Clinical Applications as Vectors for the Treatment of Malignant Gliomas

  2003cited by this paper
• DNA vaccines for cancer.

  2003cited by this paper
• A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

  2003cited by this paper
• Evidence that Replication of the Antitumor Adenovirus ONYX-015 Is Not Controlled by the p53 and p14ARF Tumor Suppressor Genes

  2002cited by this paper
• RNA viruses as virotherapy agents

  2002cited by this paper
• The emerging fields of suicide gene therapy and virotherapy.

  2002cited by this paper
• Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers.

  2002cited by this paper
• Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954.

  2001cited by this paper
• Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of Phase I and II trials

  2001cited by this paper
• Intergeneric poliovirus recombinants for the treatment of malignant glioma.

  2000cited by this paper

• Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs

  2017cites this paper
• In Vitro Synergistic enhancement of Newcastle Disease Virus to Methotrexate cytotoxicity against tumor cells

  2013cites this paper
• Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector

  2004cites this paper
• NITROREDUCTASE: A PRODRUG‐ACTIVATING ENZYME FOR CANCER GENE THERAPY

  2004cites this paper